"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL" by J R Brown

Selected Works of John M. Pagel, MD, PhD

Article

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

Leukemia (2018)

J R Brown, Harvard University
P Hillmen, Medical University of Łódź
S O’Brien, University of California, Irvine
J C Barrientos, Hofstra University
N M Reddy, Vanderbilt University
S E Coutre, Stanford University
C S Tam, Peter MacCallum Cancer Centre
S P Mulligan, Royal North Shore Hospital
U Jaeger, Medical University of Vienna
P M Barr, University of Rochester Medical Center
R R Furman, Cornell University
T J Kipps, University of California, San Diego
F Cymbalista, University of Paris
P Thornton, Beaumont Hospital
F Caligaris-Cappio, Vita-Salute San Raffaele University
J Delgado, University of Utah
M Montillo, Catholic University of the Sacred Heart
S DeVos
C Moreno, Hospital de Sant Pau
J M Pagel, Cancer Institute
T Munir
J A Burger, University of Texas MD Anderson Cancer Center
D Chung
J Lin
L Gau
B Chang, Janssen Pharmaceutica
G Cole
E Hsu
D F James, University of California, San Diego
J C Byrd, Lawrence Berkeley National Laboratory

Link

Disciplines

Publication Date

January 1, 2018

DOI

10.1038/leu.2017.175

Citation Information

J R Brown, P Hillmen, S O’Brien, J C Barrientos, et al.. "Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL" Leukemia Vol. 32 Iss. 1 (2018) p. 83 - 91
Available at: http://works.bepress.com/john-pagel/1/